Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Biogen still had a top drug candidate.
View:
Post by retiredcop on Mar 09, 2021 10:54am

Biogen still had a top drug candidate.

https://www.investors.com/news/technology/biogen-stock-why-key-medicine-blockbuster-status-2025/
Comment by M101 on Mar 09, 2021 8:56pm
That reads like paid content. No news value, no opinion, no insight. I wonder what Biogen's budget is to massage "public sentiment" before June.  Brand management makes me puke.      
Comment by retiredcop on Mar 10, 2021 9:52am
m101 ..Here is more info to make you puke. They say  " if it works ..then use it"  https://www.barrons.com/articles/what-to-watch-at-the-alzheimers-conference-besides-lilly-biogen-and-prothena-51615319747
Comment by M101 on Mar 10, 2021 12:10pm
Enjoyed the wretch, thanks. Now I'm up to date on what to think and when to think it, as are all potential pharma investors who will never hear about PMN.  It's no wonder our consutants have given up on thier overpaid jobs, except for the fees.   
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities